secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001711279-24-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M
--------------------------------------------------------------------------------

- Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.
- FDA aligned on single-arm study to approve B-VEC eyedrops for ocular DEB in ~10 patients; study starts 2H 2024.
- Cash & investments $594.1M at year-end; net income $8.7M in Q4 vs net loss of $32.1M in prior-year quarter.
- First patient dosed in Phase 1 KB408 for AATD; FDA granted ODD. Interim data expected 2H 2024.
- FY2024 non-GAAP R&D+SG&A guidance $150M-$175M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/0001711279-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/krys-20240226.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer